Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

TBX2 interacts with heterochromatin protein 1 to recruit a novel repression complex to EGR1-targeted promoters to drive the proliferation of breast cancer cells.

Crawford NT, McIntyre AJ, McCormick A, D'Costa ZC, Buckley NE, Mullan PB.

Oncogene. 2019 Jun 28. doi: 10.1038/s41388-019-0853-z. [Epub ahead of print]

PMID:
31253870
2.

NUP98 - a novel predictor of response to anthracycline-based chemotherapy in triple negative breast cancer.

Mullan PB, Bingham V, Haddock P, Irwin GW, Kay E, McQuaid S, Buckley NE.

BMC Cancer. 2019 Apr 2;19(1):236. doi: 10.1186/s12885-019-5407-9.

3.

PDLIM2 Is a Marker of Adhesion and β-Catenin Activity in Triple-Negative Breast Cancer.

Cox OT, Edmunds SJ, Simon-Keller K, Li B, Moran B, Buckley NE, Bustamante-Garrido M, Healy N, O'Flanagan CH, Gallagher WM, Kennedy RD, Bernards R, Caldas C, Chin SF, Marx A, O'Connor R.

Cancer Res. 2019 May 15;79(10):2619-2633. doi: 10.1158/0008-5472.CAN-18-2787. Epub 2019 Mar 18.

PMID:
30885980
4.

Automated Tumour Recognition and Digital Pathology Scoring Unravels New Role for PD-L1 in Predicting Good Outcome in ER-/HER2+ Breast Cancer.

Humphries MP, Hynes S, Bingham V, Cougot D, James J, Patel-Socha F, Parkes EE, Blayney JK, O'Rorke MA, Irwin GW, McArt DG, Kennedy RD, Mullan PB, McQuaid S, Salto-Tellez M, Buckley NE.

J Oncol. 2018 Dec 17;2018:2937012. doi: 10.1155/2018/2937012. eCollection 2018.

5.

Dual Mechanisms of LYN Kinase Dysregulation Drive Aggressive Behavior in Breast Cancer Cells.

Tornillo G, Knowlson C, Kendrick H, Cooke J, Mirza H, Aurrekoetxea-Rodríguez I, Vivanco MDM, Buckley NE, Grigoriadis A, Smalley MJ.

Cell Rep. 2018 Dec 26;25(13):3674-3692.e10. doi: 10.1016/j.celrep.2018.11.103.

6.

Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer.

Parkes EE, Walker SM, Taggart LE, McCabe N, Knight LA, Wilkinson R, McCloskey KD, Buckley NE, Savage KI, Salto-Tellez M, McQuaid S, Harte MT, Mullan PB, Harkin DP, Kennedy RD.

J Natl Cancer Inst. 2016 Oct 5;109(1). doi: 10.1093/jnci/djw199. Print 2017 Jan.

7.

Thromboxane A2 receptor (TBXA2R) is a potent survival factor for triple negative breast cancers (TNBCs).

Orr K, Buckley NE, Haddock P, James C, Parent JL, McQuaid S, Mullan PB.

Oncotarget. 2016 Aug 23;7(34):55458-55472. doi: 10.18632/oncotarget.10969.

8.

Quantification of HER2 heterogeneity in breast cancer-implications for identification of sub-dominant clones for personalised treatment.

Buckley NE, Forde C, McArt DG, Boyle DP, Mullan PB, James JA, Maxwell P, McQuaid S, Salto-Tellez M.

Sci Rep. 2016 Mar 21;6:23383. doi: 10.1038/srep23383.

9.

A BRCA1 deficient, NFκB driven immune signal predicts good outcome in triple negative breast cancer.

Buckley NE, Haddock P, De Matos Simoes R, Parkes E, Irwin G, Emmert-Streib F, McQuaid S, Kennedy R, Mullan P.

Oncotarget. 2016 Apr 12;7(15):19884-96. doi: 10.18632/oncotarget.7865.

10.

Garlic (Allium sativum) stimulates lipopolysaccharide-induced tumor necrosis factor-alpha production from J774A.1 murine macrophages.

Sung J, Harfouche Y, De La Cruz M, Zamora MP, Liu Y, Rego JA, Buckley NE.

Phytother Res. 2015 Feb;29(2):288-94. doi: 10.1002/ptr.5253. Epub 2014 Nov 4.

11.

Effect of Delta-9-tetrahydrocannabinol on mouse resistance to systemic Candida albicans infection.

Blumstein GW, Parsa A, Park AK, McDowell BL, Arroyo-Mendoza M, Girguis M, Adler-Moore JP, Olson J, Buckley NE.

PLoS One. 2014 Jul 24;9(7):e103288. doi: 10.1371/journal.pone.0103288. eCollection 2014.

12.

TBX2 represses CST6 resulting in uncontrolled legumain activity to sustain breast cancer proliferation: a novel cancer-selective target pathway with therapeutic opportunities.

D'Costa ZC, Higgins C, Ong CW, Irwin GW, Boyle D, McArt DG, McCloskey K, Buckley NE, Crawford NT, Thiagarajan L, Murray JT, Kennedy RD, Mulligan KA, Harkin DP, Waugh DJ, Scott CJ, Salto-Tellez M, Williams R, Mullan PB.

Oncotarget. 2014 Mar 30;5(6):1609-20.

13.

S100A2 is a BRCA1/p63 coregulated tumour suppressor gene with roles in the regulation of mutant p53 stability.

Buckley NE, D'Costa Z, Kaminska M, Mullan PB.

Cell Death Dis. 2014 Feb 20;5:e1070. doi: 10.1038/cddis.2014.31.

14.

BRCA1 is a key regulator of breast differentiation through activation of Notch signalling with implications for anti-endocrine treatment of breast cancers.

Buckley NE, Nic An tSaoir CB, Blayney JK, Oram LC, Crawford NT, D'Costa ZC, Quinn JE, Kennedy RD, Harkin DP, Mullan PB.

Nucleic Acids Res. 2013 Oct;41(18):8601-14. doi: 10.1093/nar/gkt626. Epub 2013 Jul 17.

15.

Reproduction, growth, and defense trade-offs vary with gender and reproductive allocation in Ilex glabra (Aquifoliaceae).

Buckley NE, Avila-Sakar G.

Am J Bot. 2013 Feb;100(2):357-64. doi: 10.3732/ajb.1200603. Epub 2013 Jan 17.

16.
17.

BRCA1 and GATA3 corepress FOXC1 to inhibit the pathogenesis of basal-like breast cancers.

Tkocz D, Crawford NT, Buckley NE, Berry FB, Kennedy RD, Gorski JJ, Harkin DP, Mullan PB.

Oncogene. 2012 Aug 9;31(32):3667-78. doi: 10.1038/onc.2011.531. Epub 2011 Nov 28.

PMID:
22120723
18.

The DeltaNp63 proteins are key allies of BRCA1 in the prevention of basal-like breast cancer.

Buckley NE, Conlon SJ, Jirstrom K, Kay EW, Crawford NT, O'Grady A, Sheehan K, Mc Dade SS, Wang CW, McCance DJ, Johnston PG, Kennedy RD, Harkin DP, Mullan PB.

Cancer Res. 2011 Mar 1;71(5):1933-44. doi: 10.1158/0008-5472.CAN-10-2717.

19.

Osteopontin can act as an effector for a germline mutation of BRCA1 in malignant transformation of breast cancer-related cells.

El-Tanani MK, Yuen HF, Shi Z, Platt-Higgins A, Buckley NE, Mullan PB, Harkin DP, Johnston PG, Rudland PS.

Cancer Sci. 2010 Jun;101(6):1354-60. doi: 10.1111/j.1349-7006.2010.01561.x. Epub 2010 Mar 10.

20.

T-box 2 represses NDRG1 through an EGR1-dependent mechanism to drive the proliferation of breast cancer cells.

Redmond KL, Crawford NT, Farmer H, D'Costa ZC, O'Brien GJ, Buckley NE, Kennedy RD, Johnston PG, Harkin DP, Mullan PB.

Oncogene. 2010 Jun 3;29(22):3252-62. doi: 10.1038/onc.2010.84. Epub 2010 Mar 29.

PMID:
20348948
21.

BRCA1 transcriptionally regulates genes associated with the basal-like phenotype in breast cancer.

Gorski JJ, James CR, Quinn JE, Stewart GE, Staunton KC, Buckley NE, McDyer FA, Kennedy RD, Wilson RH, Mullan PB, Harkin DP.

Breast Cancer Res Treat. 2010 Aug;122(3):721-31. doi: 10.1007/s10549-009-0565-0. Epub 2009 Oct 31.

PMID:
19882246
22.

Cannabinoid (CB2) receptor deficiency reduces the susceptibility of macrophages to oxidized LDL/oxysterol-induced apoptosis.

Freeman-Anderson NE, Pickle TG, Netherland CD, Bales A, Buckley NE, Thewke DP.

J Lipid Res. 2008 Nov;49(11):2338-46. doi: 10.1194/jlr.M800105-JLR200. Epub 2008 Jul 9.

23.

Targeting endocannabinoid degradation protects against experimental colitis in mice: involvement of CB1 and CB2 receptors.

Storr MA, Keenan CM, Emmerdinger D, Zhang H, Yüce B, Sibaev A, Massa F, Buckley NE, Lutz B, Göke B, Brand S, Patel KD, Sharkey KA.

J Mol Med (Berl). 2008 Aug;86(8):925-36. doi: 10.1007/s00109-008-0359-6. Epub 2008 May 21.

PMID:
18493729
24.

Cannabinoid CB2 receptors in the enteric nervous system modulate gastrointestinal contractility in lipopolysaccharide-treated rats.

Duncan M, Mouihate A, Mackie K, Keenan CM, Buckley NE, Davison JS, Patel KD, Pittman QJ, Sharkey KA.

Am J Physiol Gastrointest Liver Physiol. 2008 Jul;295(1):G78-G87. doi: 10.1152/ajpgi.90285.2008. Epub 2008 May 15.

25.

The cannabinoid delta-9-tetrahydrocannabinol mediates inhibition of macrophage chemotaxis to RANTES/CCL5: linkage to the CB2 receptor.

Raborn ES, Marciano-Cabral F, Buckley NE, Martin BR, Cabral GA.

J Neuroimmune Pharmacol. 2008 Jun;3(2):117-29. doi: 10.1007/s11481-007-9077-z. Epub 2007 Jul 11.

26.

The peripheral cannabinoid receptor knockout mice: an update.

Buckley NE.

Br J Pharmacol. 2008 Jan;153(2):309-18. Epub 2007 Oct 29. Review.

27.

Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells.

Maresz K, Pryce G, Ponomarev ED, Marsicano G, Croxford JL, Shriver LP, Ledent C, Cheng X, Carrier EJ, Mann MK, Giovannoni G, Pertwee RG, Yamamura T, Buckley NE, Hillard CJ, Lutz B, Baker D, Dittel BN.

Nat Med. 2007 Apr;13(4):492-7. Epub 2007 Apr 1.

PMID:
17401376
28.

BRCA1 regulates IFN-gamma signaling through a mechanism involving the type I IFNs.

Buckley NE, Hosey AM, Gorski JJ, Purcell JW, Mulligan JM, Harkin DP, Mullan PB.

Mol Cancer Res. 2007 Mar;5(3):261-70.

29.

Formation of B and T cell subsets require the cannabinoid receptor CB2.

Ziring D, Wei B, Velazquez P, Schrage M, Buckley NE, Braun J.

Immunogenetics. 2006 Sep;58(9):714-25. Epub 2006 Aug 19.

PMID:
16924491
30.

CB2 cannabinoid receptor mediation of antinociception.

Ibrahim MM, Rude ML, Stagg NJ, Mata HP, Lai J, Vanderah TW, Porreca F, Buckley NE, Makriyannis A, Malan TP Jr.

Pain. 2006 May;122(1-2):36-42. Epub 2006 Mar 23.

PMID:
16563625
31.

Experimental methods to study the role of the peripheral cannabinoid receptor in immune function.

Buckley NE, Burbridge D, Buranapramest M, Ferguson T, Paau RY.

Methods Mol Med. 2006;123:19-40.

PMID:
16506400
32.

The 2,5 oligoadenylate synthetase/RNaseL pathway is a novel effector of BRCA1- and interferon-gamma-mediated apoptosis.

Mullan PB, Hosey AM, Buckley NE, Quinn JE, Kennedy RD, Johnston PG, Harkin DP.

Oncogene. 2005 Aug 18;24(35):5492-501.

PMID:
15940267
33.

Role of cannabinoid receptors in inhibiting macrophage costimulatory activity.

Chuchawankul S, Shima M, Buckley NE, Hartmann CB, McCoy KL.

Int Immunopharmacol. 2004 Feb;4(2):265-78.

PMID:
14996418
34.

Receptors for abused drugs: development and plasticity.

Meyer JS, Slotkin TA, Buckley NE, Sircar R.

Neurotoxicol Teratol. 2000 Nov-Dec;22(6):773-84. No abstract available.

PMID:
11188756
35.

Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor.

Buckley NE, McCoy KL, Mezey E, Bonner T, Zimmer A, Felder CC, Glass M, Zimmer A.

Eur J Pharmacol. 2000 May 19;396(2-3):141-9.

PMID:
10822068
36.

Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors.

Járai Z, Wagner JA, Varga K, Lake KD, Compton DR, Martin BR, Zimmer AM, Bonner TI, Buckley NE, Mezey E, Razdan RK, Zimmer A, Kunos G.

Proc Natl Acad Sci U S A. 1999 Nov 23;96(24):14136-41.

37.

Expression of the CB1 and CB2 receptor messenger RNAs during embryonic development in the rat.

Buckley NE, Hansson S, Harta G, Mezey E.

Neuroscience. 1998 Feb;82(4):1131-49.

PMID:
9466436
38.

Involvement of sphingolipids metabolites in cellular proliferation modulated by ganglioside GM1.

Wang F, Buckley NE, Olivera A, Goodemote KA, Su Y, Spiegel S.

Glycoconj J. 1996 Dec;13(6):937-45.

PMID:
8981085
39.
40.

Signaling pathways for sphingosylphosphorylcholine-mediated mitogenesis in Swiss 3T3 fibroblasts.

Desai NN, Carlson RO, Mattie ME, Olivera A, Buckley NE, Seki T, Brooker G, Spiegel S.

J Cell Biol. 1993 Jun;121(6):1385-95.

41.
43.

Sphingosine stimulates cellular proliferation via a protein kinase C-independent pathway.

Zhang H, Buckley NE, Gibson K, Spiegel S.

J Biol Chem. 1990 Jan 5;265(1):76-81.

Supplemental Content

Loading ...
Support Center